BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31520122)

  • 1. Curettage as first surgery for bone giant cell tumor : adequate surgery is more important than oncology training or surgical management by high volume specialized teams.
    Tsukamoto S; Mavrogenis AF; Tanzi P; Leone G; Akahane M; Tanaka Y; Errani C
    Eur J Orthop Surg Traumatol; 2020 Jan; 30(1):3-9. PubMed ID: 31520122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended intralesional curettage preferred over resection-arthrodesis for giant cell tumour of the distal radius.
    Abuhejleh H; Wunder JS; Ferguson PC; Isler MH; Mottard S; Werier JA; Griffin AM; Turcotte RE
    Eur J Orthop Surg Traumatol; 2020 Jan; 30(1):11-17. PubMed ID: 31297594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soft tissue extension increases the risk of local recurrence after curettage with adjuvants for giant-cell tumor of the long bones.
    van der Heijden L; van de Sande MA; Dijkstra PD
    Acta Orthop; 2012 Aug; 83(4):401-5. PubMed ID: 22880716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
    Takeuchi A; Tsuchiya H; Ishii T; Nishida Y; Abe S; Matsumine A; Kawai A; Yoshimura K; Ueda T
    BMC Musculoskelet Disord; 2016 Jul; 17():306. PubMed ID: 27448567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgery methods and soft tissue extension are the potential risk factors of local recurrence in giant cell tumor of bone.
    Li D; Zhang J; Li Y; Xia J; Yang Y; Ren M; Liao Y; Yu S; Li X; Shen Y; Zhang Y; Yang Z
    World J Surg Oncol; 2016 Apr; 14():114. PubMed ID: 27094617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar local recurrence but better function with curettage versus resection for bone giant cell tumor and pathological fracture at presentation.
    Tsukamoto S; Mavrogenis AF; Tanzi P; Leone G; Righi A; Akahane M; Kido A; Honoki K; Tanaka Y; Donati DM; Errani C
    J Surg Oncol; 2019 Jun; 119(7):864-872. PubMed ID: 30734307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local recurrence after curettage treatment of giant cell tumors in peripheral bones: retrospective study by the GSF-GETO (French Sarcoma and Bone Tumor Study Groups).
    Gouin F; Dumaine V;
    Orthop Traumatol Surg Res; 2013 Oct; 99(6 Suppl):S313-8. PubMed ID: 23978709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-depth analysis of local recurrence of giant cell tumour of bone with soft tissue extension after intralesional curettage.
    Chen L; Ding XY; Wang CS; Si MJ; Du LJ; Zhang WB; Lu Y
    Radiol Med; 2014 Nov; 119(11):861-70. PubMed ID: 24604549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Joint preservation after extensive curettage of knee giant cell tumors.
    Ayerza MA; Aponte-Tinao LA; Farfalli GL; Restrepo CA; Muscolo DL
    Clin Orthop Relat Res; 2009 Nov; 467(11):2845-51. PubMed ID: 19513798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
    Sano K; Suehara Y; Okubo T; Sasa K; Kurihara T; Akaike K; Kubota D; Torigoe T; Hasegawa N; Ishii M; Nakamura Y; Kim Y; Takagi T; Kaneko K; Hayashi T; Saito T
    J Orthop Surg (Hong Kong); 2020; 28(2):2309499020929786. PubMed ID: 32539628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Giant cell tumor with pathologic fracture: should we curette or resect?
    van der Heijden L; Dijkstra PD; Campanacci DA; Gibbons CL; van de Sande MA
    Clin Orthop Relat Res; 2013 Mar; 471(3):820-9. PubMed ID: 22926445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical observation of surgical management for recurrent giant cell tumor of bone].
    Kong Q; Yang J; Xing R; Tu C; Zhou Y; Zhang H; Duan H
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2013 Jan; 27(1):36-40. PubMed ID: 23427489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mid-term results of intralesional extended curettage, cauterization, and polymethylmethacrylate cementation in the treatment of giant cell tumor of bone: A retrospective case series.
    Şirin E; Akgülle AH; Topkar OM; Sofulu Ö; Baykan SE; Erol B
    Acta Orthop Traumatol Turc; 2020 Sep; 54(5):524-529. PubMed ID: 33155564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of adjuvant therapies on recurrence in aneurysmal bone cysts.
    Keçeci B; Küçük L; Isayev A; Sabah D
    Acta Orthop Traumatol Turc; 2014; 48(5):500-6. PubMed ID: 25429574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Giant cell tumors combined with secondary aneurysmal bone cysts are more likely to develop postoperative recurrence: A retrospective study of 256 cases.
    Tang H; Moro A; Feng W; Lai Y; Xiao Z; Liu Y; Wang K
    J Surg Oncol; 2019 Sep; 120(3):359-365. PubMed ID: 31219620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment options for recurrent giant cell tumors of bone.
    Balke M; Ahrens H; Streitbuerger A; Koehler G; Winkelmann W; Gosheger G; Hardes J
    J Cancer Res Clin Oncol; 2009 Jan; 135(1):149-58. PubMed ID: 18521629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Convolutional neural network to predict the local recurrence of giant cell tumor of bone after curettage based on pre-surgery magnetic resonance images.
    He Y; Guo J; Ding X; van Ooijen PMA; Zhang Y; Chen A; Oudkerk M; Xie X
    Eur Radiol; 2019 Oct; 29(10):5441-5451. PubMed ID: 30859281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Strategy of Curettage and Adjuvant Microwave Therapy for the Treatment of Giant Cell Tumor of Bone in Extremities: A Preliminary Study.
    Ke J; Cheng S; Yao MY; Chu X; Wang M; Zeng XL; Yang T; Zhang C; Zhong H; Zhang Y
    Orthop Surg; 2021 Feb; 13(1):185-195. PubMed ID: 33442922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture.
    Medellin MR; Fujiwara T; Tillman RM; Jeys LM; Gregory J; Stevenson JD; Parry M; Abudu A
    Bone Joint J; 2018 Dec; 100-B(12):1626-1632. PubMed ID: 30499317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors of fracture following curettage for bone giant cell tumors of the extremities.
    Tsukamoto S; Mavrogenis AF; Akahane M; Honoki K; Kido A; Tanaka Y; Donati DM; Errani C
    BMC Musculoskelet Disord; 2022 May; 23(1):477. PubMed ID: 35590280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.